IRF8 (Interferon Regulatory Factor 8, also known as ICSBP) is a transcription factor of the IRF family that binds to interferon-stimulated response elements (ISRE), EICE (ETS-IRF composite elements with PU.1), and AICE (AP-1-IRF composite elements with BATF/JUN). It functions as both a transcriptional activator and repressor depending on context and binding partners. IRF8 is essential for myeloid and dendritic cell lineage specification, particularly for the development of plasmacytoid DCs (pDCs) and conventional DC1s (cDC1s). It regulates interferon and TLR signaling pathways and controls MHC class II antigen processing genes. Loss-of-function mutations cause immunodeficiency with dendritic cell and monocyte deficiency.
| GO Term | Evidence | Action | Reason |
|---|---|---|---|
|
GO:0002376
immune system process
|
IBA
GO_REF:0000033 |
ACCEPT |
Summary: IRF8 is a key transcription factor for immune system development and function. It is essential for myeloid and dendritic cell lineage specification [PMID:8861914], regulates interferon responses [PMID:1460054], and controls genes involved in antigen presentation [deep research: Qiu et al. 2024]. The IBA annotation reflects its well-established role across the IRF family.
Reason: IRF8 is a master regulator of immune cell development and function. Knockout mice show immunodeficiency and deregulated hematopoiesis [PMID:8861914]. Human mutations cause dendritic cell immunodeficiency [PMID:25122610]. This broad process term appropriately captures IRF8's role.
Supporting Evidence:
PMID:8861914
Mice with a null mutation of ICSBP exhibit two prominent phenotypes related to previously described activities of the IRF family. The first is enhanced susceptibility to virus infections associated with impaired production of IFN(gamma).
PMID:25122610
Laboratory evaluation revealed a highly unusual myeloid compartment, remarkable for the complete absence of CD141 and CD161 monocytes, absence of CD11c1 conventional dendritic cells (DCs) and CD11c1/CD1231 plasmacytoid DCs, and striking granulocytic hyperplasia.
file:human/IRF8/IRF8-deep-research-falcon.md
model: Edison Scientific Literature
|
|
GO:0005634
nucleus
|
IBA
GO_REF:0000033 |
ACCEPT |
Summary: IRF8 is a nuclear transcription factor that binds DNA regulatory elements. Nuclear localization is essential for its function and is well-documented [PMID:25122610, PMID:1460054].
Reason: IRF8 functions as a nuclear transcription factor. UniProt confirms nuclear localization [ECO:0000269|PubMed:23166356, ECO:0000269|PubMed:25122610]. The K108E mutation causes loss of nuclear localization, demonstrating the importance of nuclear translocation for function.
Supporting Evidence:
PMID:25122610
loss of the positively charged side chain at K108 causes loss of nuclear localization and loss of transcriptional activity
|
|
GO:0006357
regulation of transcription by RNA polymerase II
|
IBA
GO_REF:0000033 |
ACCEPT |
Summary: IRF8 regulates transcription by RNA polymerase II, acting both as an activator and repressor of target genes including interferon-inducible genes and immune cell differentiation genes [PMID:1460054].
Reason: IRF8 is a sequence-specific DNA-binding transcription factor that regulates Pol II transcription. The original 1992 paper established it as a negative regulator of ICS-containing promoters. It can both activate and repress transcription depending on context.
Supporting Evidence:
PMID:1460054
The results of transient transfection assays carried out either in hematopoietic or nonhematopoietic cells suggest that ICSBP acts as a negative regulatory factor on ICS-containing promoters.
|
|
GO:0000981
DNA-binding transcription factor activity, RNA polymerase II-specific
|
IBA
GO_REF:0000033 |
ACCEPT |
Summary: IRF8 is a DNA-binding transcription factor with an N-terminal DNA-binding domain (IRF tryptophan pentad repeat) that binds ISRE, EICE, and AICE regulatory elements [PMID:1460054, deep research].
Reason: This is a core function of IRF8. The DNA-binding domain is well-characterized (amino acids 7-114 per UniProt). IRF8 binds interferon consensus sequences and regulates Pol II transcription.
Supporting Evidence:
PMID:1460054
Truncated ICSBP lacking the first 33 amino-terminal amino acids fails to bind to the ICS, indicating that at least part of the DNA binding domain is located within the well conserved amino terminus.
|
|
GO:0000978
RNA polymerase II cis-regulatory region sequence-specific DNA binding
|
IBA
GO_REF:0000033 |
ACCEPT |
Summary: IRF8 binds specific DNA sequences including the interferon consensus sequence (ICS/ISRE), EICE (with PU.1), and AICE (with BATF/JUN) [PMID:1460054, deep research].
Reason: Sequence-specific DNA binding is well-established for IRF8. The original cloning paper demonstrated binding to ICS elements. More recent work shows binding to composite EICE and AICE motifs with partner transcription factors.
Supporting Evidence:
PMID:1460054
A murine cDNA which encodes an ICS binding protein has been reported (M-ICSBP). The cloning of the human homologue of ICSBP (H-ICSBP) is described.
|
|
GO:0000976
transcription cis-regulatory region binding
|
IEA
GO_REF:0000002 |
ACCEPT |
Summary: IEA annotation from InterPro mapping. IRF8 binds cis-regulatory regions including ISRE, EICE, and AICE elements.
Reason: This is a parent term of the more specific GO:0000978 (RNA polymerase II cis-regulatory region sequence-specific DNA binding). The IEA annotation is consistent with IRF8's known DNA-binding function and supported by IBA annotation to the child term.
|
|
GO:0000978
RNA polymerase II cis-regulatory region sequence-specific DNA binding
|
IEA
GO_REF:0000117 |
ACCEPT |
Summary: IEA annotation from ARBA machine learning models, consistent with IBA annotation to the same term.
Reason: This duplicates the IBA annotation to GO:0000978. The IEA evidence provides additional support from computational methods. Both are valid.
|
|
GO:0003677
DNA binding
|
IEA
GO_REF:0000120 |
ACCEPT |
Summary: General DNA binding annotation from combined IEA methods. IRF8 has a well-characterized DNA-binding domain (IRF tryptophan pentad repeat, aa 7-114).
Reason: This is a parent term of the more specific sequence-specific DNA binding terms. While general, it is accurate. More specific child terms are also annotated.
|
|
GO:0003700
DNA-binding transcription factor activity
|
IEA
GO_REF:0000120 |
ACCEPT |
Summary: IEA annotation for general transcription factor activity. IRF8 is a DNA-binding transcription factor that can activate or repress transcription.
Reason: This is a parent term of GO:0000981 (DNA-binding transcription factor activity, RNA polymerase II-specific). Accurate but less specific than the IBA annotation.
|
|
GO:0005634
nucleus
|
IEA
GO_REF:0000120 |
ACCEPT |
Summary: IEA annotation for nuclear localization, consistent with IBA and IDA annotations to the same term.
Reason: Duplicates IBA annotation. Nuclear localization is well-established for IRF8 as a transcription factor.
|
|
GO:0005737
cytoplasm
|
IEA
GO_REF:0000044 |
ACCEPT |
Summary: IEA annotation from UniProt subcellular location vocabulary. IRF8 is found in cytoplasm in resting cells and translocates to nucleus upon IFN-gamma stimulation.
Reason: UniProt states IRF8 localizes in the cytoplasm in resting macrophages and translocates to the nucleus upon IFN-gamma induction. This cytoplasmic localization is accurate for unstimulated cells.
|
|
GO:0006355
regulation of DNA-templated transcription
|
IEA
GO_REF:0000002 |
ACCEPT |
Summary: IEA annotation from InterPro. IRF8 regulates transcription as a DNA-binding transcription factor.
Reason: This is a parent term of GO:0006357 (regulation of transcription by RNA polymerase II). Consistent with IRF8's core function as a transcription factor.
|
|
GO:0006914
autophagy
|
IEA
GO_REF:0000043 |
MARK AS OVER ANNOTATED |
Summary: IEA annotation based on UniProt keyword mapping. UniProt lists "Autophagy" as a keyword based on one paper [PMID:29434592] showing IRF8 positively regulates macroautophagy in dendritic cells. However, IRF8 is a transcription factor that may regulate autophagy gene expression, not a direct autophagy component.
Reason: IRF8 is a transcription factor for immune cell differentiation, not an autophagy pathway component. The UniProt annotation is based on a single paper showing IRF8 can positively regulate autophagy in DCs, but this is a downstream effect of its transcription factor activity, not a core function. The term "autophagy" without qualifier implies direct involvement in the autophagy process. A more appropriate annotation would be "regulation of autophagy" if warranted.
|
|
GO:0006955
immune response
|
IEA
GO_REF:0000117 |
ACCEPT |
Summary: IEA annotation from ARBA. IRF8 regulates immune responses through its role in interferon signaling and immune cell development.
Reason: IRF8 is critical for immune responses, controlling interferon-inducible gene expression and immune cell differentiation. This is consistent with the IBA annotation to GO:0002376 (immune system process).
|
|
GO:0098542
defense response to other organism
|
IEA
GO_REF:0000117 |
KEEP AS NON CORE |
Summary: IEA annotation from ARBA. IRF8 is important for defense against pathogens through its role in interferon responses and immune cell development.
Reason: While IRF8 is important for antimicrobial defense (IRF8 mutations cause mycobacterial susceptibility), this is a downstream consequence of its role as a transcription factor for immune cell development, not a direct molecular function. Defense response is a secondary process.
Supporting Evidence:
PMID:8861914
enhanced susceptibility to virus infections associated with impaired production of IFN(gamma)
|
|
GO:0005515
protein binding
|
IPI
PMID:21903422 Mapping a dynamic innate immunity protein interaction networ... |
REMOVE |
Summary: IPI annotation from HI5 interactome mapping study. This was a high-throughput proteomics study mapping innate immunity protein interactions. IRF8 was one of many proteins analyzed.
Reason: "Protein binding" (GO:0005515) is uninformative without specifying the binding partner or functional context. The HI5 study was a high-throughput interactome mapping that does not provide specific functional insights for IRF8. More informative annotations for IRF8's protein interactions exist (e.g., with PU.1, BATF, JUNB). This vague annotation should be replaced with specific partner annotations.
Supporting Evidence:
PMID:21903422
2011 Sep 8. Mapping a dynamic innate immunity protein interaction network regulating type I interferon production.
|
|
GO:0005515
protein binding
|
IPI
PMID:32814053 Interactome Mapping Provides a Network of Neurodegenerative ... |
REMOVE |
Summary: IPI annotation from a neurodegenerative disease interactome mapping study that included IRF8 as one of many proteins analyzed via yeast two-hybrid.
Reason: This high-throughput interactome study focused on neurodegenerative disease proteins. IRF8 is not a neurodegeneration protein; it is an immune transcription factor. The "protein binding" annotation from this study provides no meaningful functional information about IRF8's actual binding partners (PU.1, BATF, JUNB, etc.).
Supporting Evidence:
PMID:32814053
Interactome Mapping Provides a Network of Neurodegenerative Disease Proteins and Uncovers Widespread Protein Aggregation in Affected Brains.
|
|
GO:0000122
negative regulation of transcription by RNA polymerase II
|
IEA
GO_REF:0000120 |
ACCEPT |
Summary: IEA annotation for transcriptional repression. IRF8 was originally identified as a negative regulator of ICS-containing promoters [PMID:1460054].
Reason: IRF8 acts as a transcriptional repressor in certain contexts, including repression of interferon-inducible genes and osteoclast differentiation factors. This is well-documented experimentally and supported by IDA annotations.
Supporting Evidence:
PMID:1460054
ICSBP acts as a negative regulatory factor on ICS-containing promoters
|
|
GO:0000977
RNA polymerase II transcription regulatory region sequence-specific DNA binding
|
IEA
GO_REF:0000107 |
ACCEPT |
Summary: IEA annotation from Ensembl Compara ortholog transfer. IRF8 binds specific DNA sequences in transcription regulatory regions.
Reason: Equivalent to GO:0000978 (RNA polymerase II cis-regulatory region sequence-specific DNA binding). Consistent with IBA and IDA annotations to related terms. IRF8 binds ISRE, EICE, and AICE elements.
|
|
GO:0002273
plasmacytoid dendritic cell differentiation
|
IEA
GO_REF:0000107 |
ACCEPT |
Summary: IEA annotation from ortholog transfer. IRF8 is essential for pDC development, as demonstrated by loss of pDCs in IRF8-deficient mice and humans [PMID:25122610, file:human/IRF8/IRF8-deep-research-falcon.md].
Reason: This is a core function of IRF8. Human patients with IRF8 mutations lack circulating pDCs. Mouse knockouts also lack pDCs. This is well-supported by both human and mouse studies.
Supporting Evidence:
PMID:25122610
Laboratory evaluation revealed a highly unusual myeloid compartment, remarkable for the complete absence of CD141 and CD161 monocytes, absence of CD11c1 conventional dendritic cells (DCs) and CD11c1/CD1231 plasmacytoid DCs, and striking granulocytic hyperplasia.
|
|
GO:0002314
germinal center B cell differentiation
|
IEA
GO_REF:0000107 |
KEEP AS NON CORE |
Summary: IEA annotation from ortholog transfer. IRF8 is expressed in B cells and involved in B cell development, including germinal center reactions.
Reason: IRF8 is expressed in B cells and plays roles in B cell biology, but its primary functions are in myeloid and dendritic cell lineages. B cell differentiation is a secondary role. The deep research mentions IRF8 involvement in germinal center programs and B cell lymphoma antigen presentation, but myeloid/DC specification is the core function.
|
|
GO:0002316
follicular B cell differentiation
|
IEA
GO_REF:0000107 |
KEEP AS NON CORE |
Summary: IEA annotation from ortholog transfer for follicular B cell differentiation.
Reason: Similar to germinal center B cell differentiation - IRF8 has roles in B cell biology but its core functions are in myeloid/DC lineage specification. This represents a secondary function in B cell development.
|
|
GO:0032479
regulation of type I interferon production
|
IEA
GO_REF:0000107 |
ACCEPT |
Summary: IEA annotation from ortholog transfer. IRF8 regulates type I interferon responses through its role in pDC development (major IFN-I producers) and direct transcriptional regulation.
Reason: IRF8 is essential for pDC development, and pDCs are the major producers of type I interferons. Additionally, IRF8 directly regulates interferon-inducible genes. This is a well-established function.
Supporting Evidence:
PMID:1460054
The promoter regions of many interferon-inducible genes share a short DNA sequence motif, termed the interferon consensus sequence (ICS) to which several regulatory proteins bind.
|
|
GO:0043065
positive regulation of apoptotic process
|
IEA
GO_REF:0000107 |
KEEP AS NON CORE |
Summary: IEA annotation from ortholog transfer for apoptosis regulation.
Reason: IRF8 has been implicated in apoptosis regulation in some contexts, but this is not a core function. Its primary roles are in transcriptional regulation of immune cell differentiation and interferon responses. Apoptosis effects may be secondary consequences.
|
|
GO:0045944
positive regulation of transcription by RNA polymerase II
|
IEA
GO_REF:0000120 |
ACCEPT |
Summary: IEA annotation for transcriptional activation. IRF8 can act as a transcriptional activator in certain contexts, particularly for immune response genes.
Reason: IRF8 functions as both activator and repressor depending on context. UniProt states it "Can both act as a transcriptional activator or repressor." The K108E mutation causes loss of transcriptional activity, demonstrating wild-type IRF8 has activator function.
Supporting Evidence:
PMID:25122610
Biochemical characterization of the IRF8(K108E) mutant in vitro shows that loss of the positively charged side chain at K108 causes loss of nuclear localization and loss of transcriptional activity
|
|
GO:0071346
cellular response to type II interferon
|
IEA
GO_REF:0000107 |
ACCEPT |
Summary: IEA annotation from ortholog transfer. IRF8 expression is induced by IFN-gamma and it mediates IFN-gamma transcriptional responses [PMID:1460054].
Reason: IRF8 is induced by IFN-gamma and translocates to the nucleus upon IFN-gamma stimulation to regulate target genes. IFN treatment alleviates ICSBP-mediated repression.
Supporting Evidence:
PMID:1460054
either interferon-gamma (IFN-gamma) or IFN-beta can alleviate the repression mediated by ICSBP
|
|
GO:0097028
dendritic cell differentiation
|
IEA
GO_REF:0000107 |
ACCEPT |
Summary: IEA annotation from ortholog transfer. IRF8 is essential for dendritic cell development, particularly cDC1 and pDC lineages [PMID:25122610, deep research].
Reason: This is a core function of IRF8. Human IRF8 mutations cause DC deficiency. Mouse knockouts lack cDC1 and pDC populations. IRF8 programs enhancers for DC lineage specification.
Supporting Evidence:
PMID:25122610
absence of CD11c1 conventional dendritic cells (DCs) and CD11c1/CD1231 plasmacytoid DCs
|
|
GO:0005654
nucleoplasm
|
IDA
GO_REF:0000052 |
ACCEPT |
Summary: IDA annotation from HPA immunofluorescence data. IRF8 localizes to the nucleoplasm as a transcription factor.
Reason: As a DNA-binding transcription factor, IRF8 functions in the nucleoplasm where it binds chromatin. This is consistent with its molecular function.
|
|
GO:0005515
protein binding
|
IPI
PMID:33951726 Constrained chromatin accessibility in PU.1-mutated agammagl... |
MODIFY |
Summary: IPI annotation for protein binding, specifically with PU.1/SPI1. The study characterized PU.1 mutations in agammaglobulinemia and showed IRF8 interaction with PU.1.
Reason: While this annotation captures a real interaction, "protein binding" is too vague. IRF8 interacts with PU.1 to bind EICE composite elements and regulate gene expression. A more specific term like "DNA-binding transcription factor binding" or annotation with specific interaction context would be more informative.
Proposed replacements:
DNA-binding transcription factor binding
Supporting Evidence:
PMID:33951726
May 5. Constrained chromatin accessibility in PU.1-mutated agammaglobulinemia patients.
|
|
GO:0002273
plasmacytoid dendritic cell differentiation
|
ISS
GO_REF:0000024 |
ACCEPT |
Summary: ISS annotation from manual ortholog transfer. pDC differentiation is essential function of IRF8.
Reason: Duplicates the IEA annotation with different evidence (manual ortholog transfer). pDC differentiation is a well-established core function of IRF8.
|
|
GO:0032479
regulation of type I interferon production
|
ISS
GO_REF:0000024 |
ACCEPT |
Summary: ISS annotation from manual ortholog transfer. IRF8 regulates type I IFN production.
Reason: Duplicates the IEA annotation with different evidence. Type I IFN regulation is well-established.
|
|
GO:0097028
dendritic cell differentiation
|
ISS
GO_REF:0000024 |
ACCEPT |
Summary: ISS annotation from manual ortholog transfer. DC differentiation is a core IRF8 function.
Reason: Duplicates the IEA annotation with different evidence. DC differentiation is a core function of IRF8 supported by human and mouse genetic evidence.
|
|
GO:1990837
sequence-specific double-stranded DNA binding
|
IDA
PMID:28473536 Impact of cytosine methylation on DNA binding specificities ... |
ACCEPT |
Summary: IDA annotation from a systematic study of transcription factor DNA binding specificities using SELEX. The study examined 542 human TFs including IRF8.
Reason: IRF8 binds specific DNA sequences (ISRE, EICE, AICE elements) as double-stranded DNA. This systematic study provides direct evidence for sequence-specific binding.
Supporting Evidence:
PMID:28473536
Impact of cytosine methylation on DNA binding specificities of human transcription factors.
|
|
GO:0000785
chromatin
|
ISA
GO_REF:0000113 |
ACCEPT |
Summary: ISA annotation from TFClass database for transcription factors. IRF8 binds chromatin at regulatory elements.
Reason: As a transcription factor, IRF8 functions at chromatin, binding enhancers and promoters. Deep research describes IRF8's role in chromatin accessibility and enhancer programming.
|
|
GO:0000981
DNA-binding transcription factor activity, RNA polymerase II-specific
|
ISA
GO_REF:0000113 |
ACCEPT |
Summary: ISA annotation from TFClass database. IRF8 is classified as a sequence-specific DNA-binding transcription factor.
Reason: Duplicates IBA annotation. This is a core molecular function of IRF8.
|
|
GO:0000122
negative regulation of transcription by RNA polymerase II
|
IDA
PMID:1460054 Human interferon consensus sequence binding protein is a neg... |
ACCEPT |
Summary: IDA annotation from the original IRF8/ICSBP cloning paper showing it acts as a transcriptional repressor of interferon-inducible genes.
Reason: The original characterization paper demonstrated that ICSBP/IRF8 acts as a negative regulator of ICS-containing promoters. This is direct experimental evidence.
Supporting Evidence:
PMID:1460054
The results of transient transfection assays carried out either in hematopoietic or nonhematopoietic cells suggest that ICSBP acts as a negative regulatory factor on ICS-containing promoters.
|
|
GO:0000122
negative regulation of transcription by RNA polymerase II
|
IDA
PMID:25122610 Functional characterization of the human dendritic cell immu... |
ACCEPT |
Summary: IDA annotation from functional characterization of human IRF8 K108E mutation showing loss of transcriptional activity.
Reason: The study characterized IRF8 function by showing that the K108E mutation causes loss of transcriptional activity, demonstrating that wild-type IRF8 has transcriptional regulatory function.
Supporting Evidence:
PMID:25122610
Biochemical characterization of the IRF8(K108E) mutant in vitro shows that loss of the positively charged side chain at K108 causes loss of nuclear localization and loss of transcriptional activity
|
|
GO:0005634
nucleus
|
IDA
PMID:25122610 Functional characterization of the human dendritic cell immu... |
ACCEPT |
Summary: IDA annotation for nuclear localization from the K108E mutation study showing IRF8 requires nuclear localization for function.
Reason: Direct experimental evidence for nuclear localization and its importance for function. The K108E mutation causes loss of nuclear localization.
Supporting Evidence:
PMID:25122610
loss of the positively charged side chain at K108 causes loss of nuclear localization and loss of transcriptional activity
|
|
GO:0005737
cytoplasm
|
IDA
PMID:25122610 Functional characterization of the human dendritic cell immu... |
ACCEPT |
Summary: IDA annotation for cytoplasmic localization in resting cells before IFN-gamma stimulation.
Reason: IRF8 is found in the cytoplasm in resting cells. The K108E mutation affects nuclear translocation, indicating normal IRF8 shuttles between cytoplasm and nucleus.
Supporting Evidence:
PMID:25122610
Functional characterization of the human dendritic cell immunodeficiency associated with the IRF8(K108E) mutation.
|
|
GO:0045944
positive regulation of transcription by RNA polymerase II
|
IDA
PMID:25122610 Functional characterization of the human dendritic cell immu... |
ACCEPT |
Summary: IDA annotation for transcriptional activation function, demonstrated by loss of transcriptional activity in K108E mutant.
Reason: The K108E mutation study showed loss of transcriptional activity, demonstrating that wild-type IRF8 can activate transcription.
Supporting Evidence:
PMID:25122610
loss of the positively charged side chain at K108 causes loss of nuclear localization and loss of transcriptional activity
|
|
GO:0071346
cellular response to type II interferon
|
IDA
PMID:25122610 Functional characterization of the human dendritic cell immu... |
ACCEPT |
Summary: IDA annotation for IFN-gamma response, showing IRF8 is involved in interferon-regulated transcription.
Reason: The study shows IRF8 regulates IRF8-bound and IRF8-regulated transcriptional targets that are depleted in the patient, demonstrating its role in interferon responses.
Supporting Evidence:
PMID:25122610
depletion of IRF8-bound and IRF8-regulated transcriptional targets
|
|
GO:0000978
RNA polymerase II cis-regulatory region sequence-specific DNA binding
|
IDA
PMID:1460054 Human interferon consensus sequence binding protein is a neg... |
ACCEPT |
Summary: IDA annotation for sequence-specific DNA binding to the interferon consensus sequence (ICS).
Reason: The original cloning paper demonstrated that ICSBP binds to ICS elements and that truncation of the N-terminus eliminates DNA binding.
Supporting Evidence:
PMID:1460054
Truncated ICSBP lacking the first 33 amino-terminal amino acids fails to bind to the ICS
|
|
GO:0001227
DNA-binding transcription repressor activity, RNA polymerase II-specific
|
IDA
PMID:1460054 Human interferon consensus sequence binding protein is a neg... |
ACCEPT |
Summary: IDA annotation for transcriptional repressor activity based on the original cloning paper.
Reason: The original paper established ICSBP/IRF8 as a transcriptional repressor of ICS-containing promoters. This molecular function is well-documented.
Supporting Evidence:
PMID:1460054
ICSBP acts as a negative regulatory factor on ICS-containing promoters
|
|
GO:0005829
cytosol
|
TAS
Reactome:R-HSA-1015702 |
ACCEPT |
Summary: TAS annotation from Reactome pathway for expression of IFN-induced genes. IRF8 is present in cytosol in unstimulated cells.
Reason: Consistent with IDA annotation showing cytoplasmic localization in resting cells. Cytosol is a subcompartment of cytoplasm.
|
|
GO:0005829
cytosol
|
TAS
Reactome:R-HSA-1031716 |
ACCEPT |
Summary: TAS annotation from Reactome pathway for expression of IFNG-stimulated genes.
Reason: Duplicate of above annotation from different Reactome pathway. Cytosolic localization is consistent with other evidence.
|
|
GO:0000122
negative regulation of transcription by RNA polymerase II
|
TAS
PMID:1460054 Human interferon consensus sequence binding protein is a neg... |
ACCEPT |
Summary: TAS annotation for transcriptional repression, citing the original ICSBP cloning paper.
Reason: This is a duplicate of the IDA annotation to the same term from the same reference. The original paper established IRF8 as a transcriptional repressor.
Supporting Evidence:
PMID:1460054
Human interferon consensus sequence binding protein is a negative regulator of enhancer elements common to interferon-inducible genes.
|
|
GO:0000981
DNA-binding transcription factor activity, RNA polymerase II-specific
|
TAS
PMID:1460054 Human interferon consensus sequence binding protein is a neg... |
ACCEPT |
Summary: TAS annotation for transcription factor activity from the original cloning paper.
Reason: This duplicates IBA and ISA annotations. The original paper established IRF8 as a DNA-binding transcription factor.
Supporting Evidence:
PMID:1460054
Human interferon consensus sequence binding protein is a negative regulator of enhancer elements common to interferon-inducible genes.
|
|
GO:0006955
immune response
|
TAS
PMID:8861914 Immunodeficiency and chronic myelogenous leukemia-like syndr... |
ACCEPT |
Summary: TAS annotation for immune response based on the mouse knockout study showing immunodeficiency.
Reason: The mouse knockout study demonstrated IRF8's essential role in immune function, including virus susceptibility and impaired IFN-gamma production.
Supporting Evidence:
PMID:8861914
enhanced susceptibility to virus infections associated with impaired production of IFN(gamma)
|
Q: What are the specific enhancer elements and chromatin accessibility changes controlled by IRF8 in human DC progenitors?
Q: How do IRF8 interactions with different partners (PU.1 vs BATF) determine activator vs repressor function?
Q: What is the relationship between IRF8 and MHC class II antigen processing gene regulation in human DCs?
Experiment: ChIP-seq analysis of IRF8 binding sites in human monocyte-derived DCs with and without IFN-gamma stimulation
Experiment: CRISPR screens in human hematopoietic progenitors to identify IRF8-dependent genes for DC differentiation
Experiment: Structural studies of IRF8-DNA-partner complexes to understand composite element recognition
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2026-01-19T09:50:36.762440'
end_time: '2026-01-19T09:57:39.649315'
duration_seconds: 422.89
template_file: templates/gene_research_go_focused.md
template_variables:
organism: human
gene_id: IRF8
gene_symbol: IRF8
uniprot_accession: Q02556
protein_description: 'RecName: Full=Interferon regulatory factor 8 {ECO:0000305};
Short=IRF-8; AltName: Full=Interferon consensus sequence-binding protein {ECO:0000303|PubMed:1460054};
Short=H-ICSBP {ECO:0000303|PubMed:1460054}; Short=ICSBP {ECO:0000303|PubMed:1460054};'
gene_info: Name=IRF8 {ECO:0000303|PubMed:21524210, ECO:0000312|HGNC:HGNC:5358};
Synonyms=ICSBP1 {ECO:0000303|PubMed:1460054};
organism_full: Homo sapiens (Human).
protein_family: Belongs to the IRF family. {ECO:0000255|PROSITE-
protein_domains: Interferon_reg_fac_CS. (IPR019817); Interferon_reg_fact_DNA-bd_dom.
(IPR001346); Interferon_reg_factor-3. (IPR019471); SMAD-like_dom_sf. (IPR017855);
SMAD_FHA_dom_sf. (IPR008984)
provider_config:
timeout: 600
max_retries: 3
parameters:
allowed_domains: []
temperature: 0.1
citation_count: 24
BEFORE YOU BEGIN RESEARCH: You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.
DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE. Instead:
- State clearly: "The gene symbol 'IRF8' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information
Please provide a comprehensive research report on the gene IRF8 (gene ID: IRF8, UniProt: Q02556) in human.
The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.
You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.
We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.
We are interested in where in or outside the cell the gene product carries out its function.
We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.
Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.
Question: You are an expert researcher providing comprehensive, well-cited information.
Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies
Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.
BEFORE YOU BEGIN RESEARCH: You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.
DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE. Instead:
- State clearly: "The gene symbol 'IRF8' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information
Please provide a comprehensive research report on the gene IRF8 (gene ID: IRF8, UniProt: Q02556) in human.
The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.
You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.
We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.
We are interested in where in or outside the cell the gene product carries out its function.
We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.
Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.
Plan status: We verified identity, collected recent literature (2023–2024 priority), extracted mechanistic and disease evidence, and synthesized into a structured report with citations.
Comprehensive research report: Human IRF8 (UniProt Q02556)
Gene/protein verification and identity
- Symbol and accession: IRF8 (also ICSBP/ICSBP1), Homo sapiens; structural analyses in 2024 B‑cell lymphoma study explicitly reference the human protein model AF‑Q02556‑F1 (UniProt Q02556), confirming the correct gene/protein identity (https://doi.org/10.1126/sciadv.adk2091). The study aligns the IRF8 DNA‑binding domain (DBD) to DNA‑bound IRF3, supporting conserved IRF DBD features (helix–turn–helix fold) (qiu2024irf8mutantbcell pages 17-18, qiu2024irf8mutantbcell pages 1-2).
- Domains/family: IRF8 is an IRF family transcription factor with an N‑terminal DBD and a C‑terminal IRF‑association domain (IAD) that mediates protein–protein interactions and dimerization; it binds ISRE, EICE (PU.1–IRF), and AICE (AP‑1–IRF) composite motifs (reviewed 2023) (https://doi.org/10.1097/moh.0000000000000763) (johnson2023interferonregulatoryfactor8dependent pages 3-4). Structural/biophysical inferences in lymphoma models corroborate DBD function and pathogenic impacts of DBD/IAD mutations on promoter binding (qiu2024irf8mutantbcell pages 1-2, qiu2024irf8mutantbcell pages 17-18).
- Cellular localization: IRF8 acts as a nuclear transcription factor in hematopoietic/myeloid lineages and microglia, with well‑characterized nuclear DNA binding and enhancer occupancy (e.g., CUT&RUN in microglia) (https://doi.org/10.1101/2023.06.25.546453) (saeki2024irf8configuresenhancer pages 1-5).
Primary molecular functions and mechanisms
- DNA binding and motif grammar: IRF8 binds ISRE sequences and composite elements EICE (with PU.1/ETS) and AICE (with AP‑1 family members, e.g., BATF/JUN); the IAD supports partner‑selection that determines activation vs repression (https://doi.org/10.1097/moh.0000000000000763) (johnson2023interferonregulatoryfactor8dependent pages 3-4). In B‑cell lymphoma, pathogenic IRF8 mutants reduce promoter occupancy at CD74 and HLA‑DM, impairing MHC‑II antigen processing (https://doi.org/10.1126/sciadv.adk2091) (qiu2024irf8mutantbcell pages 1-2, qiu2024irf8mutantbcell pages 17-18).
- Chromatin and enhancer programming: In mice, low IRF8 expression emerges in LMPPs, epigenetically opening enhancers of dendritic‑cell (DC) lineage genes; loss of Irf8 collapses cDC1/pDC differentiation while biasing granulopoiesis (https://doi.org/10.1182/blood-2018-06-857789) (kurotaki2019epigeneticcontrolof pages 1-5, kurotaki2019epigeneticcontrolof pages 8-12). In postnatal microglia, IRF8 binds enhancers with Sall1 and PU.1 in a stepwise fashion after birth, configuring microglia‑specific chromatin landscapes; deletion disrupts microglial identity programs (https://doi.org/10.1101/2023.06.25.546453) (saeki2024irf8configuresenhancer pages 1-5).
Pathways and cellular roles
- Interferon and TLR signaling: IRF8 participates in type I/II interferon and TLR pathways; through PU.1/AP‑1 partnerships, it induces IFNγ‑responsive genes and orchestrates myeloid lineage decisions (reviewed 2023) (https://doi.org/10.1097/moh.0000000000000763) (johnson2023interferonregulatoryfactor8dependent pages 3-4).
- Hematopoiesis and lineage choice: IRF8 is essential for mononuclear phagocyte specification, promoting monocyte/DC programs and repressing neutrophil differentiation (in part by countering C/EBPα). Irf8–/– mice accumulate neutrophil‑like cells and lose pDCs and CD8α+ cDC1s; early IRF8 expression in LMPPs epigenetically biases toward cDC1 fate (Blood 2019) (kurotaki2019epigeneticcontrolof pages 1-5, kurotaki2019epigeneticcontrolof pages 8-12, johnson2023interferonregulatoryfactor8dependent pages 3-4). In human immunodeficiency due to IRF8 variants, absent circulating pDCs and reduced IL‑12/IFN‑γ responses underscore IRF8’s role in DC‑dependent cytokine circuits (https://doi.org/10.3389/fimmu.2025.1654617) (chiang2025casereporta pages 9-10, chiang2025casereporta pages 1-2).
- Microglia: IRF8 is highly expressed in microglia, directing enhancer configuration and maintaining microglial identity; postnatal deletion induces disease‑associated microglia‑like gene signatures and reduces plaque interactions in a 5xFAD context (bioRxiv 2024) (https://doi.org/10.1101/2023.06.25.546453) (saeki2024irf8configuresenhancer pages 1-5).
Disease links and human genetics
- Inborn errors of immunity (monogenic): Pathogenic IRF8 variants (biallelic recessive or dominant‑negative) cause dendritic‑cell/monocyte deficiency and Mendelian susceptibility to mycobacterial disease (MSMD), with clinical features including absent pDCs, impaired IL‑12/IFN‑γ production, neutrophil skewing, and broad infectious susceptibility (Frontiers in Immunology 2025 case report and referenced literature) (https://doi.org/10.3389/fimmu.2025.1654617) (chiang2025casereporta pages 9-10, chiang2025casereporta pages 1-2).
- Autoimmune disease genetics (2023–2024): IRF8 is implicated by GWAS and functional genomics in systemic sclerosis (SSc). A 2024 Japanese‑led GWAS and meta‑analysis identified IRF8‑related regulatory elements in B cells (e.g., a cis‑regulatory SNP rs10917688 in LD with FCGR/FCRL signal; enrichment of IRF8‑binding sites improves PRS fit) (Nature Communications 2024; https://doi.org/10.1038/s41467-023-44541-z). Contemporary reviews summarize IRF8 SSc associations, enhancer dysregulation, and cell‑type chromatin interactions (Journal of Molecular Pathology 2024; https://doi.org/10.3390/jmp5010008) (mennella2024theroleof pages 7-9, mennella2024theroleof pages 11-13).
- Cancer biology (antigen presentation and immune evasion): Recurrent IRF8 mutations in diffuse large B‑cell lymphoma (DLBCL) disrupt CD74 and HLA‑DM expression, selectively dampening CD4+ T‑cell activation and remodeling the tumor microenvironment (mouse models and human DLBCL deconvolution) (Science Advances 2024; https://doi.org/10.1126/sciadv.adk2091) (qiu2024irf8mutantbcell pages 1-2, qiu2024irf8mutantbcell pages 17-18). These data mechanistically link IRF8 dysfunction to MHC‑II antigen processing defects and immune escape.
Current applications and real‑world implementations
- Transcription factor–mediated reprogramming to cDC1‑like APCs: Forced expression of PU.1–IRF8–BATF3 (PIB) reprograms diverse human and mouse tumor cell lines (36 lines) into cDC1‑like tumor‑APCs within nine days, restoring endogenous antigen presentation on MHC‑I, enabling cross‑presentation to naïve CD8+ T cells, and promoting tumor‑infiltrating lymphocyte activation. Tumor‑APCs exhibit reduced tumorigenicity; intratumoral administration delays tumor growth and improves survival, synergizing with immune checkpoint blockade in mice (Science Immunology 2023; https://doi.org/10.1126/sciimmunol.add4817) (zimmermannova2023restoringtumorimmunogenicity pages 1-3).
- DC‑targeted therapy in lung tumors: DC‑therapy (Flt3L + αCD40) expands cDC1 and reduces CD8 exhaustion in murine lung cancer; a cDC1 transcriptional signature that includes Batf3 and Irf8 stratifies responses, underscoring IRF8‑dependent cDC1 biology as a therapeutic axis (Nature Communications 2024; https://doi.org/10.1038/s41467-024-46685-y) (zimmermannova2023restoringtumorimmunogenicity pages 1-3).
Expert opinions and mechanistic analyses (authoritative sources)
- Hematopoiesis/IFN circuitry: A 2023 expert review details IRF8’s domain architecture, composite motif usage (ISRE/EICE/AICE), and partner‑dependent lineage control in myeloid cells; it integrates enhancer logic at the Irf8 locus (e.g., +56 kb site) and places IRF8 at the intersection of IFNγ, TLR, and AP‑1/ETS programs (https://doi.org/10.1097/moh.0000000000000763) (johnson2023interferonregulatoryfactor8dependent pages 3-4).
- DC ontogeny and epigenetics: Single‑cell and ATAC‑seq data show IRF8 primes DC enhancers in LMPPs and is necessary for cDC1/pDC output; these mechanistic data remain a reference for IRF8’s role in early DC lineage specification (Blood 2019; https://doi.org/10.1182/blood-2018-06-857789) (kurotaki2019epigeneticcontrolof pages 1-5, kurotaki2019epigeneticcontrolof pages 8-12).
- Microglia epigenome: Postnatal enhancer programming by IRF8 establishes microglial identity and regulates disease‑associated gene programs (bioRxiv 2024; https://doi.org/10.1101/2023.06.25.546453) (saeki2024irf8configuresenhancer pages 1-5).
Relevant statistics and data points
- Reprogramming efficacy: PIB reprogramming was demonstrated across 36 cancer cell lines; cDC1‑like features emerged within nine days, with in vivo tumor‑growth delay and survival benefit, and synergy with checkpoint inhibitors (Sci Immunol 2023) (zimmermannova2023restoringtumorimmunogenicity pages 1-3).
- B‑cell lymphoma immune evasion: IRF8 mutants reduced CD74 and HLA‑DM transcription and impaired CD4 activation in murine models; tumors exhibited increased burden and depletion of effector lymphocytes with Treg/Tfh increases, revealing functional consequences of IRF8 loss on antigen processing/presentation (Sci Adv 2024) (qiu2024irf8mutantbcell pages 1-2).
- DC lineage bias: IRF8+ LMPPs preferentially yield cDC1, while Irf8–/– LMPPs fail to generate cDC1 and instead produce neutrophils, indicating early chromatin‑level priming by IRF8 (Blood 2019) (kurotaki2019epigeneticcontrolof pages 1-5, kurotaki2019epigeneticcontrolof pages 8-12).
- Immunodeficiency readouts: A 2025 case with de novo heterozygous IRF8 c.1182dup variant had absent circulating pDCs and reduced IL‑12p70 and IFN‑γ secretion; findings align with prior dominant‑negative IRF8 cases and the spectrum of IRF8‑related inborn errors of immunity (Front Immunol 2025) (chiang2025casereporta pages 9-10, chiang2025casereporta pages 1-2).
- Systemic sclerosis genetics: 2024 GWAS identified an Asian lead signal in FCGR/FCRL with LD to a cis‑regulatory element for IRF8; prioritizing IRF8‑binding SNPs in B cells improved PRS performance in meta‑analysis, implicating IRF8‑centered regulation in SSc susceptibility (Nat Commun 2024) (mennella2024theroleof pages 7-9).
Focused functional annotation
- Primary function: IRF8 is a nuclear transcriptional regulator, not an enzyme/transport protein. Its biochemical specificity is encoded by its DBD/IAD and by partner selection (PU.1/BATF/JUN), enabling binding to ISRE/EICE/AICE elements to activate or repress lineage‑ and stimulus‑specific gene programs (johnson2023interferonregulatoryfactor8dependent pages 3-4).
- Subcellular and tissue context: Predominantly nuclear in hematopoietic cells (monocytes, macrophages, DCs, B‑cell subsets) and CNS microglia; functions at cis‑regulatory modules (enhancers/promoters) to configure chromatin accessibility and transcription (saeki2024irf8configuresenhancer pages 1-5, kurotaki2019epigeneticcontrolof pages 1-5).
- Pathways: Orchestrates interferon and TLR responses (type I/II IFN genes), IL‑12 production and downstream IFN‑γ circuits in antigen‑presenting cells; in B cells influences GC programs and MHC‑II antigen processing through control of CD74/HLA‑DM (johnson2023interferonregulatoryfactor8dependent pages 3-4, qiu2024irf8mutantbcell pages 1-2).
Notes on diagnostic markers and IHC
- In surgical pathology, IRF8 is widely used as a nuclear marker of myeloid/DC lineage in marrow and lymphoid tissues, but specificity varies by context. While it is commonly positive in plasmacytoid dendritic cells and BPDCN, it is not specific when used alone; panels incorporating lineage‑defining markers are recommended (AJCP 2023 study on pDC/BPDCN immunophenotypes; URL: https://doi.org/10.1093/ajcp/aqac174). (This paragraph is included for context; sensitivity/specificity metrics derive from the cited 2023 study.)
Key recent developments (2023–2024)
- Tumor cell reprogramming to cDC1‑like APCs via PU.1–IRF8–BATF3 (PIB) as a therapeutic concept with demonstrated in vivo efficacy and checkpoint synergy (Sci Immunol 2023) (zimmermannova2023restoringtumorimmunogenicity pages 1-3).
- Mechanistic cancer immunology: IRF8 mutations in DLBCL as a driver of MHC‑II antigen‑processing defects and immune escape (Sci Adv 2024) (qiu2024irf8mutantbcell pages 1-2, qiu2024irf8mutantbcell pages 17-18).
- Microglia enhancer programming and identity maintenance by IRF8, with functional consequences in neurodegeneration models (bioRxiv 2024) (saeki2024irf8configuresenhancer pages 1-5).
- SSc genetics: cross‑population GWAS/meta‑analysis highlighting IRF8‑centered regulatory architecture in B cells and improved PRS when prioritizing IRF8‑binding SNPs (Nat Commun 2024) (mennella2024theroleof pages 7-9).
Real‑world and translational outlook
- Biomarker/diagnostics: IRF8 immunostaining supports identification of myeloid/DC lineages in hematopathology but should be interpreted in panels due to limited specificity in some entities; IRF8 mutation testing may inform immune‑evasion mechanisms in B‑cell lymphomas (qiu2024irf8mutantbcell pages 1-2).
- Therapeutics: DC‑axis therapies that expand/activate cDC1 (Flt3L + αCD40) leverage IRF8‑dependent cDC1 biology; TF‑based reprogramming (PIB) represents a platform for restoring tumor immunogenicity and synergizing with checkpoint blockade in preclinical models (zimmermannova2023restoringtumorimmunogenicity pages 1-3).
Cited sources (URLs and dates)
- Qiu et al., Science Advances, 2024-07: IRF8 mutant DLBCL alters CD74/HLA‑DM and MHC‑II antigen presentation; AlphaFold AF‑Q02556‑F1 used (https://doi.org/10.1126/sciadv.adk2091) (qiu2024irf8mutantbcell pages 1-2, qiu2024irf8mutantbcell pages 17-18).
- Zimmermannova et al., Science Immunology, 2023-07: PU.1–IRF8–BATF3 reprogramming to cDC1‑like tumor‑APCs; 36 cell lines; in vivo synergy with ICI (https://doi.org/10.1126/sciimmunol.add4817) (zimmermannova2023restoringtumorimmunogenicity pages 1-3).
- Kurotaki et al., Blood, 2019-04: IRF8 primes DC lineage at LMPP stage via enhancer opening; cDC1/pDC dependence (https://doi.org/10.1182/blood-2018-06-857789) (kurotaki2019epigeneticcontrolof pages 1-5, kurotaki2019epigeneticcontrolof pages 8-12).
- Johnson et al., Curr Opin Hematol, 2023-04: Domain architecture and composite motif usage (ISRE/EICE/AICE) and lineage control (https://doi.org/10.1097/moh.0000000000000763) (johnson2023interferonregulatoryfactor8dependent pages 3-4).
- Saeki et al., bioRxiv, 2024-08: IRF8 configures enhancer landscape in postnatal microglia (https://doi.org/10.1101/2023.06.25.546453) (saeki2024irf8configuresenhancer pages 1-5).
- Ishikawa et al., Nat Commun, 2024-01: SSc GWAS; B‑cell IRF8‑binding SNP prioritization improves PRS (https://doi.org/10.1038/s41467-023-44541-z); see also review synthesis (https://doi.org/10.3390/jmp5010008) (mennella2024theroleof pages 7-9, mennella2024theroleof pages 11-13).
- Chiang et al., Frontiers in Immunology, 2025-10: Case report expanding IRF8 heterozygous variant spectrum; absent pDCs and impaired IL‑12/IFN‑γ in one case (https://doi.org/10.3389/fimmu.2025.1654617) (chiang2025casereporta pages 9-10, chiang2025casereporta pages 1-2).
Ambiguity check and alignment with UniProt record
- The literature above explicitly concerns human IRF8 and mouse ortholog in mechanistic studies; the 2024 lymphoma paper employs the human model AF‑Q02556‑F1, matching UniProt Q02556. Reported domains (DBD, IAD) and IRF‑family membership align with the UniProt description. No conflicting gene symbol usage was identified (qiu2024irf8mutantbcell pages 17-18, johnson2023interferonregulatoryfactor8dependent pages 3-4).
References
(qiu2024irf8mutantbcell pages 17-18): Zhijun Qiu, Jihane Khalife, Purushoth Ethiraj, Carine Jaafar, An-Ping Lin, Kenneth N. Holder, Jacob P. Ritter, Lilly Chiou, Gabriela Huelgas-Morales, Sadia Aslam, Zhao Zhang, Zhijie Liu, Shailee Arya, Yogesh K. Gupta, Patricia L. M. Dahia, and Ricardo C.T. Aguiar. Irf8-mutant b cell lymphoma evades immunity through a cd74-dependent deregulation of antigen processing and presentation in mhcii complexes. Science Advances, Jul 2024. URL: https://doi.org/10.1126/sciadv.adk2091, doi:10.1126/sciadv.adk2091. This article has 13 citations and is from a highest quality peer-reviewed journal.
(qiu2024irf8mutantbcell pages 1-2): Zhijun Qiu, Jihane Khalife, Purushoth Ethiraj, Carine Jaafar, An-Ping Lin, Kenneth N. Holder, Jacob P. Ritter, Lilly Chiou, Gabriela Huelgas-Morales, Sadia Aslam, Zhao Zhang, Zhijie Liu, Shailee Arya, Yogesh K. Gupta, Patricia L. M. Dahia, and Ricardo C.T. Aguiar. Irf8-mutant b cell lymphoma evades immunity through a cd74-dependent deregulation of antigen processing and presentation in mhcii complexes. Science Advances, Jul 2024. URL: https://doi.org/10.1126/sciadv.adk2091, doi:10.1126/sciadv.adk2091. This article has 13 citations and is from a highest quality peer-reviewed journal.
(johnson2023interferonregulatoryfactor8dependent pages 3-4): Kirby D. Johnson, Mabel M. Jung, Vu L. Tran, and Emery H. Bresnick. Interferon regulatory factor-8-dependent innate immune alarm senses gata2 deficiency to alter hematopoietic differentiation and function. Current Opinion in Hematology, 30:117-123, Apr 2023. URL: https://doi.org/10.1097/moh.0000000000000763, doi:10.1097/moh.0000000000000763. This article has 8 citations and is from a peer-reviewed journal.
(saeki2024irf8configuresenhancer pages 1-5): Keita Saeki, Richard Pan, Eunju Lee, Daisuke Kurotaki, and Keiko Ozato. Irf8 configures enhancer landscape in postnatal microglia and directs microglia specific transcriptional programs. bioRxiv, Aug 2024. URL: https://doi.org/10.1101/2023.06.25.546453, doi:10.1101/2023.06.25.546453. This article has 8 citations and is from a poor quality or predatory journal.
(kurotaki2019epigeneticcontrolof pages 1-5): Daisuke Kurotaki, Wataru Kawase, Haruka Sasaki, Jun Nakabayashi, Akira Nishiyama, Herbert C. Morse, Keiko Ozato, Yutaka Suzuki, and Tomohiko Tamura. Epigenetic control of early dendritic cell lineage specification by the transcription factor irf8 in mice. Blood, 133 17:1803-1813, Apr 2019. URL: https://doi.org/10.1182/blood-2018-06-857789, doi:10.1182/blood-2018-06-857789. This article has 73 citations and is from a highest quality peer-reviewed journal.
(kurotaki2019epigeneticcontrolof pages 8-12): Daisuke Kurotaki, Wataru Kawase, Haruka Sasaki, Jun Nakabayashi, Akira Nishiyama, Herbert C. Morse, Keiko Ozato, Yutaka Suzuki, and Tomohiko Tamura. Epigenetic control of early dendritic cell lineage specification by the transcription factor irf8 in mice. Blood, 133 17:1803-1813, Apr 2019. URL: https://doi.org/10.1182/blood-2018-06-857789, doi:10.1182/blood-2018-06-857789. This article has 73 citations and is from a highest quality peer-reviewed journal.
(chiang2025casereporta pages 9-10): Samuel C. C. Chiang, Erika Owsley, Ammar Husami, Nagako Akeno, Cristina M. Cobb, Li Yang, Rebecca A. Marsh, Kenneth A. Myers, and Tamar S. Rubin. Case report: a patient with a novel heterozygous irf8 variant with repeated infection and immune-mediated organ disease, but without disseminated mycobacterial disease despite bcg immunization. Frontiers in Immunology, Oct 2025. URL: https://doi.org/10.3389/fimmu.2025.1654617, doi:10.3389/fimmu.2025.1654617. This article has 0 citations and is from a peer-reviewed journal.
(chiang2025casereporta pages 1-2): Samuel C. C. Chiang, Erika Owsley, Ammar Husami, Nagako Akeno, Cristina M. Cobb, Li Yang, Rebecca A. Marsh, Kenneth A. Myers, and Tamar S. Rubin. Case report: a patient with a novel heterozygous irf8 variant with repeated infection and immune-mediated organ disease, but without disseminated mycobacterial disease despite bcg immunization. Frontiers in Immunology, Oct 2025. URL: https://doi.org/10.3389/fimmu.2025.1654617, doi:10.3389/fimmu.2025.1654617. This article has 0 citations and is from a peer-reviewed journal.
(mennella2024theroleof pages 7-9): Anna Mennella, Giuseppe Ocone, Katia Stefanantoni, and Loredana Frasca. The role of irf8 polymorphisms in systemic sclerosis development and pathogenesis. Journal of Molecular Pathology, 5:120-132, Mar 2024. URL: https://doi.org/10.3390/jmp5010008, doi:10.3390/jmp5010008. This article has 1 citations.
(mennella2024theroleof pages 11-13): Anna Mennella, Giuseppe Ocone, Katia Stefanantoni, and Loredana Frasca. The role of irf8 polymorphisms in systemic sclerosis development and pathogenesis. Journal of Molecular Pathology, 5:120-132, Mar 2024. URL: https://doi.org/10.3390/jmp5010008, doi:10.3390/jmp5010008. This article has 1 citations.
(zimmermannova2023restoringtumorimmunogenicity pages 1-3): Olga Zimmermannova, Alexandra G. Ferreira, Ervin Ascic, Marta Velasco Santiago, Ilia Kurochkin, Morten Hansen, Özcan Met, Inês Caiado, Ilja E. Shapiro, Justine Michaux, Marion Humbert, Diego Soto-Cabrera, Hreinn Benonisson, Rita Silvério-Alves, David Gomez-Jimenez, Carina Bernardo, Monika Bauden, Roland Andersson, Mattias Höglund, Kenichi Miharada, Yukio Nakamura, Stephanie Hugues, Lennart Greiff, Malin Lindstedt, Fábio F. Rosa, Cristiana F. Pires, Michal Bassani-Sternberg, Inge Marie Svane, and Carlos-Filipe Pereira. Restoring tumor immunogenicity with dendritic cell reprogramming. Science Immunology, Jul 2023. URL: https://doi.org/10.1126/sciimmunol.add4817, doi:10.1126/sciimmunol.add4817. This article has 75 citations and is from a highest quality peer-reviewed journal.
id: Q02556
gene_symbol: IRF8
product_type: PROTEIN
status: COMPLETE
taxon:
id: NCBITaxon:9606
label: Homo sapiens
description: >-
IRF8 (Interferon Regulatory Factor 8, also known as ICSBP) is a transcription factor
of the IRF family
that binds to interferon-stimulated response elements (ISRE), EICE (ETS-IRF composite
elements with PU.1),
and AICE (AP-1-IRF composite elements with BATF/JUN). It functions as both a transcriptional
activator and
repressor depending on context and binding partners. IRF8 is essential for myeloid
and dendritic cell lineage
specification, particularly for the development of plasmacytoid DCs (pDCs) and conventional
DC1s (cDC1s).
It regulates interferon and TLR signaling pathways and controls MHC class II antigen
processing genes.
Loss-of-function mutations cause immunodeficiency with dendritic cell and monocyte
deficiency.
existing_annotations:
- term:
id: GO:0002376
label: immune system process
evidence_type: IBA
original_reference_id: GO_REF:0000033
review:
summary: >-
IRF8 is a key transcription factor for immune system development and function.
It is essential for
myeloid and dendritic cell lineage specification [PMID:8861914], regulates
interferon responses
[PMID:1460054], and controls genes involved in antigen presentation [deep
research: Qiu et al. 2024].
The IBA annotation reflects its well-established role across the IRF family.
action: ACCEPT
reason: >-
IRF8 is a master regulator of immune cell development and function. Knockout
mice show immunodeficiency
and deregulated hematopoiesis [PMID:8861914]. Human mutations cause dendritic
cell immunodeficiency
[PMID:25122610]. This broad process term appropriately captures IRF8's role.
supported_by:
- reference_id: PMID:8861914
supporting_text: "Mice with a null mutation of ICSBP exhibit two prominent
phenotypes related to previously described activities of the IRF family.
The first is enhanced susceptibility to virus infections associated with
impaired production of IFN(gamma)."
- reference_id: PMID:25122610
supporting_text: "Laboratory evaluation revealed a highly unusual myeloid
compartment, remarkable for the complete absence of CD141 and CD161 monocytes,
absence of CD11c1 conventional dendritic cells (DCs) and CD11c1/CD1231
plasmacytoid DCs, and striking granulocytic hyperplasia."
- reference_id: file:human/IRF8/IRF8-deep-research-falcon.md
supporting_text: 'model: Edison Scientific Literature'
- term:
id: GO:0005634
label: nucleus
evidence_type: IBA
original_reference_id: GO_REF:0000033
review:
summary: >-
IRF8 is a nuclear transcription factor that binds DNA regulatory elements.
Nuclear localization
is essential for its function and is well-documented [PMID:25122610, PMID:1460054].
action: ACCEPT
reason: >-
IRF8 functions as a nuclear transcription factor. UniProt confirms nuclear
localization [ECO:0000269|PubMed:23166356,
ECO:0000269|PubMed:25122610]. The K108E mutation causes loss of nuclear localization,
demonstrating
the importance of nuclear translocation for function.
supported_by:
- reference_id: PMID:25122610
supporting_text: "loss of the positively charged side chain at K108 causes
loss of nuclear localization and loss of transcriptional activity"
- term:
id: GO:0006357
label: regulation of transcription by RNA polymerase II
evidence_type: IBA
original_reference_id: GO_REF:0000033
review:
summary: >-
IRF8 regulates transcription by RNA polymerase II, acting both as an activator
and repressor of
target genes including interferon-inducible genes and immune cell differentiation
genes [PMID:1460054].
action: ACCEPT
reason: >-
IRF8 is a sequence-specific DNA-binding transcription factor that regulates
Pol II transcription.
The original 1992 paper established it as a negative regulator of ICS-containing
promoters.
It can both activate and repress transcription depending on context.
supported_by:
- reference_id: PMID:1460054
supporting_text: "The results of transient transfection assays carried out
either in hematopoietic or nonhematopoietic cells suggest that ICSBP acts
as a negative regulatory factor on ICS-containing promoters."
- term:
id: GO:0000981
label: DNA-binding transcription factor activity, RNA polymerase
II-specific
evidence_type: IBA
original_reference_id: GO_REF:0000033
review:
summary: >-
IRF8 is a DNA-binding transcription factor with an N-terminal DNA-binding
domain (IRF tryptophan
pentad repeat) that binds ISRE, EICE, and AICE regulatory elements [PMID:1460054,
deep research].
action: ACCEPT
reason: >-
This is a core function of IRF8. The DNA-binding domain is well-characterized
(amino acids 7-114
per UniProt). IRF8 binds interferon consensus sequences and regulates Pol
II transcription.
supported_by:
- reference_id: PMID:1460054
supporting_text: "Truncated ICSBP lacking the first 33 amino-terminal amino
acids fails to bind to the ICS, indicating that at least part of the DNA
binding domain is located within the well conserved amino terminus."
- term:
id: GO:0000978
label: RNA polymerase II cis-regulatory region sequence-specific DNA
binding
evidence_type: IBA
original_reference_id: GO_REF:0000033
review:
summary: >-
IRF8 binds specific DNA sequences including the interferon consensus sequence
(ICS/ISRE),
EICE (with PU.1), and AICE (with BATF/JUN) [PMID:1460054, deep research].
action: ACCEPT
reason: >-
Sequence-specific DNA binding is well-established for IRF8. The original cloning
paper demonstrated
binding to ICS elements. More recent work shows binding to composite EICE
and AICE motifs with
partner transcription factors.
supported_by:
- reference_id: PMID:1460054
supporting_text: "A murine cDNA which encodes an ICS binding protein has
been reported (M-ICSBP). The cloning of the human homologue of ICSBP (H-ICSBP)
is described."
- term:
id: GO:0000976
label: transcription cis-regulatory region binding
evidence_type: IEA
original_reference_id: GO_REF:0000002
review:
summary: >-
IEA annotation from InterPro mapping. IRF8 binds cis-regulatory regions including
ISRE, EICE,
and AICE elements.
action: ACCEPT
reason: >-
This is a parent term of the more specific GO:0000978 (RNA polymerase II cis-regulatory
region
sequence-specific DNA binding). The IEA annotation is consistent with IRF8's
known DNA-binding
function and supported by IBA annotation to the child term.
- term:
id: GO:0000978
label: RNA polymerase II cis-regulatory region sequence-specific DNA
binding
evidence_type: IEA
original_reference_id: GO_REF:0000117
review:
summary: >-
IEA annotation from ARBA machine learning models, consistent with IBA annotation
to the same term.
action: ACCEPT
reason: >-
This duplicates the IBA annotation to GO:0000978. The IEA evidence provides
additional support
from computational methods. Both are valid.
- term:
id: GO:0003677
label: DNA binding
evidence_type: IEA
original_reference_id: GO_REF:0000120
review:
summary: >-
General DNA binding annotation from combined IEA methods. IRF8 has a well-characterized
DNA-binding domain (IRF tryptophan pentad repeat, aa 7-114).
action: ACCEPT
reason: >-
This is a parent term of the more specific sequence-specific DNA binding terms.
While general,
it is accurate. More specific child terms are also annotated.
- term:
id: GO:0003700
label: DNA-binding transcription factor activity
evidence_type: IEA
original_reference_id: GO_REF:0000120
review:
summary: >-
IEA annotation for general transcription factor activity. IRF8 is a DNA-binding
transcription
factor that can activate or repress transcription.
action: ACCEPT
reason: >-
This is a parent term of GO:0000981 (DNA-binding transcription factor activity,
RNA polymerase
II-specific). Accurate but less specific than the IBA annotation.
- term:
id: GO:0005634
label: nucleus
evidence_type: IEA
original_reference_id: GO_REF:0000120
review:
summary: >-
IEA annotation for nuclear localization, consistent with IBA and IDA annotations
to the same term.
action: ACCEPT
reason: >-
Duplicates IBA annotation. Nuclear localization is well-established for IRF8
as a transcription factor.
- term:
id: GO:0005737
label: cytoplasm
evidence_type: IEA
original_reference_id: GO_REF:0000044
review:
summary: >-
IEA annotation from UniProt subcellular location vocabulary. IRF8 is found
in cytoplasm in
resting cells and translocates to nucleus upon IFN-gamma stimulation.
action: ACCEPT
reason: >-
UniProt states IRF8 localizes in the cytoplasm in resting macrophages and
translocates to the
nucleus upon IFN-gamma induction. This cytoplasmic localization is accurate
for unstimulated cells.
- term:
id: GO:0006355
label: regulation of DNA-templated transcription
evidence_type: IEA
original_reference_id: GO_REF:0000002
review:
summary: >-
IEA annotation from InterPro. IRF8 regulates transcription as a DNA-binding
transcription factor.
action: ACCEPT
reason: >-
This is a parent term of GO:0006357 (regulation of transcription by RNA polymerase
II).
Consistent with IRF8's core function as a transcription factor.
- term:
id: GO:0006914
label: autophagy
evidence_type: IEA
original_reference_id: GO_REF:0000043
review:
summary: >-
IEA annotation based on UniProt keyword mapping. UniProt lists "Autophagy"
as a keyword based on
one paper [PMID:29434592] showing IRF8 positively regulates macroautophagy
in dendritic cells.
However, IRF8 is a transcription factor that may regulate autophagy gene expression,
not a
direct autophagy component.
action: MARK_AS_OVER_ANNOTATED
reason: >-
IRF8 is a transcription factor for immune cell differentiation, not an autophagy
pathway component.
The UniProt annotation is based on a single paper showing IRF8 can positively
regulate autophagy
in DCs, but this is a downstream effect of its transcription factor activity,
not a core function.
The term "autophagy" without qualifier implies direct involvement in the autophagy
process.
A more appropriate annotation would be "regulation of autophagy" if warranted.
- term:
id: GO:0006955
label: immune response
evidence_type: IEA
original_reference_id: GO_REF:0000117
review:
summary: >-
IEA annotation from ARBA. IRF8 regulates immune responses through its role
in interferon signaling
and immune cell development.
action: ACCEPT
reason: >-
IRF8 is critical for immune responses, controlling interferon-inducible gene
expression and
immune cell differentiation. This is consistent with the IBA annotation to
GO:0002376 (immune
system process).
- term:
id: GO:0098542
label: defense response to other organism
evidence_type: IEA
original_reference_id: GO_REF:0000117
review:
summary: >-
IEA annotation from ARBA. IRF8 is important for defense against pathogens
through its role in
interferon responses and immune cell development.
action: KEEP_AS_NON_CORE
reason: >-
While IRF8 is important for antimicrobial defense (IRF8 mutations cause mycobacterial
susceptibility),
this is a downstream consequence of its role as a transcription factor for
immune cell development,
not a direct molecular function. Defense response is a secondary process.
supported_by:
- reference_id: PMID:8861914
supporting_text: "enhanced susceptibility to virus infections associated
with impaired production of IFN(gamma)"
- term:
id: GO:0005515
label: protein binding
evidence_type: IPI
original_reference_id: PMID:21903422
review:
summary: >-
IPI annotation from HI5 interactome mapping study. This was a high-throughput
proteomics study
mapping innate immunity protein interactions. IRF8 was one of many proteins
analyzed.
action: REMOVE
reason: >-
"Protein binding" (GO:0005515) is uninformative without specifying the binding
partner or
functional context. The HI5 study was a high-throughput interactome mapping
that does not
provide specific functional insights for IRF8. More informative annotations
for IRF8's
protein interactions exist (e.g., with PU.1, BATF, JUNB). This vague annotation
should
be replaced with specific partner annotations.
supported_by:
- reference_id: PMID:21903422
supporting_text: 2011 Sep 8. Mapping a dynamic innate immunity protein
interaction network regulating type I interferon production.
- term:
id: GO:0005515
label: protein binding
evidence_type: IPI
original_reference_id: PMID:32814053
review:
summary: >-
IPI annotation from a neurodegenerative disease interactome mapping study
that included
IRF8 as one of many proteins analyzed via yeast two-hybrid.
action: REMOVE
reason: >-
This high-throughput interactome study focused on neurodegenerative disease
proteins.
IRF8 is not a neurodegeneration protein; it is an immune transcription factor.
The
"protein binding" annotation from this study provides no meaningful functional
information
about IRF8's actual binding partners (PU.1, BATF, JUNB, etc.).
supported_by:
- reference_id: PMID:32814053
supporting_text: Interactome Mapping Provides a Network of
Neurodegenerative Disease Proteins and Uncovers Widespread Protein
Aggregation in Affected Brains.
- term:
id: GO:0000122
label: negative regulation of transcription by RNA polymerase II
evidence_type: IEA
original_reference_id: GO_REF:0000120
review:
summary: >-
IEA annotation for transcriptional repression. IRF8 was originally identified
as a negative
regulator of ICS-containing promoters [PMID:1460054].
action: ACCEPT
reason: >-
IRF8 acts as a transcriptional repressor in certain contexts, including repression
of
interferon-inducible genes and osteoclast differentiation factors. This is
well-documented
experimentally and supported by IDA annotations.
supported_by:
- reference_id: PMID:1460054
supporting_text: "ICSBP acts as a negative regulatory factor on ICS-containing
promoters"
- term:
id: GO:0000977
label: RNA polymerase II transcription regulatory region sequence-specific
DNA binding
evidence_type: IEA
original_reference_id: GO_REF:0000107
review:
summary: >-
IEA annotation from Ensembl Compara ortholog transfer. IRF8 binds specific
DNA sequences
in transcription regulatory regions.
action: ACCEPT
reason: >-
Equivalent to GO:0000978 (RNA polymerase II cis-regulatory region sequence-specific
DNA binding).
Consistent with IBA and IDA annotations to related terms. IRF8 binds ISRE,
EICE, and AICE elements.
- term:
id: GO:0002273
label: plasmacytoid dendritic cell differentiation
evidence_type: IEA
original_reference_id: GO_REF:0000107
review:
summary: >-
IEA annotation from ortholog transfer. IRF8 is essential for pDC development,
as demonstrated
by loss of pDCs in IRF8-deficient mice and humans [PMID:25122610, file:human/IRF8/IRF8-deep-research-falcon.md].
action: ACCEPT
reason: >-
This is a core function of IRF8. Human patients with IRF8 mutations lack circulating
pDCs.
Mouse knockouts also lack pDCs. This is well-supported by both human and mouse
studies.
supported_by:
- reference_id: PMID:25122610
supporting_text: "Laboratory evaluation revealed a highly unusual myeloid
compartment, remarkable for the complete absence of CD141 and CD161 monocytes,
absence of CD11c1 conventional dendritic cells (DCs) and CD11c1/CD1231
plasmacytoid DCs, and striking granulocytic hyperplasia."
- term:
id: GO:0002314
label: germinal center B cell differentiation
evidence_type: IEA
original_reference_id: GO_REF:0000107
review:
summary: >-
IEA annotation from ortholog transfer. IRF8 is expressed in B cells and involved
in B cell
development, including germinal center reactions.
action: KEEP_AS_NON_CORE
reason: >-
IRF8 is expressed in B cells and plays roles in B cell biology, but its primary
functions are
in myeloid and dendritic cell lineages. B cell differentiation is a secondary
role. The deep
research mentions IRF8 involvement in germinal center programs and B cell
lymphoma antigen
presentation, but myeloid/DC specification is the core function.
- term:
id: GO:0002316
label: follicular B cell differentiation
evidence_type: IEA
original_reference_id: GO_REF:0000107
review:
summary: >-
IEA annotation from ortholog transfer for follicular B cell differentiation.
action: KEEP_AS_NON_CORE
reason: >-
Similar to germinal center B cell differentiation - IRF8 has roles in B cell
biology but
its core functions are in myeloid/DC lineage specification. This represents
a secondary
function in B cell development.
- term:
id: GO:0032479
label: regulation of type I interferon production
evidence_type: IEA
original_reference_id: GO_REF:0000107
review:
summary: >-
IEA annotation from ortholog transfer. IRF8 regulates type I interferon responses
through
its role in pDC development (major IFN-I producers) and direct transcriptional
regulation.
action: ACCEPT
reason: >-
IRF8 is essential for pDC development, and pDCs are the major producers of
type I interferons.
Additionally, IRF8 directly regulates interferon-inducible genes. This is
a well-established function.
supported_by:
- reference_id: PMID:1460054
supporting_text: "The promoter regions of many interferon-inducible genes
share a short DNA sequence motif, termed the interferon consensus sequence
(ICS) to which several regulatory proteins bind."
- term:
id: GO:0043065
label: positive regulation of apoptotic process
evidence_type: IEA
original_reference_id: GO_REF:0000107
review:
summary: >-
IEA annotation from ortholog transfer for apoptosis regulation.
action: KEEP_AS_NON_CORE
reason: >-
IRF8 has been implicated in apoptosis regulation in some contexts, but this
is not a core
function. Its primary roles are in transcriptional regulation of immune cell
differentiation
and interferon responses. Apoptosis effects may be secondary consequences.
- term:
id: GO:0045944
label: positive regulation of transcription by RNA polymerase II
evidence_type: IEA
original_reference_id: GO_REF:0000120
review:
summary: >-
IEA annotation for transcriptional activation. IRF8 can act as a transcriptional
activator
in certain contexts, particularly for immune response genes.
action: ACCEPT
reason: >-
IRF8 functions as both activator and repressor depending on context. UniProt
states it
"Can both act as a transcriptional activator or repressor." The K108E mutation
causes
loss of transcriptional activity, demonstrating wild-type IRF8 has activator
function.
supported_by:
- reference_id: PMID:25122610
supporting_text: "Biochemical characterization of the IRF8(K108E) mutant
in vitro shows that loss of the positively charged side chain at K108
causes loss of nuclear localization and loss of transcriptional activity"
- term:
id: GO:0071346
label: cellular response to type II interferon
evidence_type: IEA
original_reference_id: GO_REF:0000107
review:
summary: >-
IEA annotation from ortholog transfer. IRF8 expression is induced by IFN-gamma
and it mediates
IFN-gamma transcriptional responses [PMID:1460054].
action: ACCEPT
reason: >-
IRF8 is induced by IFN-gamma and translocates to the nucleus upon IFN-gamma
stimulation to
regulate target genes. IFN treatment alleviates ICSBP-mediated repression.
supported_by:
- reference_id: PMID:1460054
supporting_text: "either interferon-gamma (IFN-gamma) or IFN-beta can alleviate
the repression mediated by ICSBP"
- term:
id: GO:0097028
label: dendritic cell differentiation
evidence_type: IEA
original_reference_id: GO_REF:0000107
review:
summary: >-
IEA annotation from ortholog transfer. IRF8 is essential for dendritic cell
development,
particularly cDC1 and pDC lineages [PMID:25122610, deep research].
action: ACCEPT
reason: >-
This is a core function of IRF8. Human IRF8 mutations cause DC deficiency.
Mouse knockouts
lack cDC1 and pDC populations. IRF8 programs enhancers for DC lineage specification.
supported_by:
- reference_id: PMID:25122610
supporting_text: "absence of CD11c1 conventional dendritic cells (DCs) and
CD11c1/CD1231 plasmacytoid DCs"
- term:
id: GO:0005654
label: nucleoplasm
evidence_type: IDA
original_reference_id: GO_REF:0000052
review:
summary: >-
IDA annotation from HPA immunofluorescence data. IRF8 localizes to the nucleoplasm
as a
transcription factor.
action: ACCEPT
reason: >-
As a DNA-binding transcription factor, IRF8 functions in the nucleoplasm where
it binds
chromatin. This is consistent with its molecular function.
- term:
id: GO:0005515
label: protein binding
evidence_type: IPI
original_reference_id: PMID:33951726
review:
summary: >-
IPI annotation for protein binding, specifically with PU.1/SPI1. The study
characterized
PU.1 mutations in agammaglobulinemia and showed IRF8 interaction with PU.1.
action: MODIFY
reason: >-
While this annotation captures a real interaction, "protein binding" is too
vague. IRF8
interacts with PU.1 to bind EICE composite elements and regulate gene expression.
A more
specific term like "DNA-binding transcription factor binding" or annotation
with specific
interaction context would be more informative.
proposed_replacement_terms:
- id: GO:0140297
label: DNA-binding transcription factor binding
supported_by:
- reference_id: PMID:33951726
supporting_text: May 5. Constrained chromatin accessibility in
PU.1-mutated agammaglobulinemia patients.
- term:
id: GO:0002273
label: plasmacytoid dendritic cell differentiation
evidence_type: ISS
original_reference_id: GO_REF:0000024
review:
summary: >-
ISS annotation from manual ortholog transfer. pDC differentiation is essential
function of IRF8.
action: ACCEPT
reason: >-
Duplicates the IEA annotation with different evidence (manual ortholog transfer).
pDC
differentiation is a well-established core function of IRF8.
- term:
id: GO:0032479
label: regulation of type I interferon production
evidence_type: ISS
original_reference_id: GO_REF:0000024
review:
summary: >-
ISS annotation from manual ortholog transfer. IRF8 regulates type I IFN production.
action: ACCEPT
reason: >-
Duplicates the IEA annotation with different evidence. Type I IFN regulation
is well-established.
- term:
id: GO:0097028
label: dendritic cell differentiation
evidence_type: ISS
original_reference_id: GO_REF:0000024
review:
summary: >-
ISS annotation from manual ortholog transfer. DC differentiation is a core
IRF8 function.
action: ACCEPT
reason: >-
Duplicates the IEA annotation with different evidence. DC differentiation
is a core function
of IRF8 supported by human and mouse genetic evidence.
- term:
id: GO:1990837
label: sequence-specific double-stranded DNA binding
evidence_type: IDA
original_reference_id: PMID:28473536
review:
summary: >-
IDA annotation from a systematic study of transcription factor DNA binding
specificities
using SELEX. The study examined 542 human TFs including IRF8.
action: ACCEPT
reason: >-
IRF8 binds specific DNA sequences (ISRE, EICE, AICE elements) as double-stranded
DNA.
This systematic study provides direct evidence for sequence-specific binding.
supported_by:
- reference_id: PMID:28473536
supporting_text: Impact of cytosine methylation on DNA binding
specificities of human transcription factors.
- term:
id: GO:0000785
label: chromatin
evidence_type: ISA
original_reference_id: GO_REF:0000113
review:
summary: >-
ISA annotation from TFClass database for transcription factors. IRF8 binds
chromatin at
regulatory elements.
action: ACCEPT
reason: >-
As a transcription factor, IRF8 functions at chromatin, binding enhancers
and promoters.
Deep research describes IRF8's role in chromatin accessibility and enhancer
programming.
- term:
id: GO:0000981
label: DNA-binding transcription factor activity, RNA polymerase
II-specific
evidence_type: ISA
original_reference_id: GO_REF:0000113
review:
summary: >-
ISA annotation from TFClass database. IRF8 is classified as a sequence-specific
DNA-binding
transcription factor.
action: ACCEPT
reason: >-
Duplicates IBA annotation. This is a core molecular function of IRF8.
- term:
id: GO:0000122
label: negative regulation of transcription by RNA polymerase II
evidence_type: IDA
original_reference_id: PMID:1460054
review:
summary: >-
IDA annotation from the original IRF8/ICSBP cloning paper showing it acts
as a transcriptional
repressor of interferon-inducible genes.
action: ACCEPT
reason: >-
The original characterization paper demonstrated that ICSBP/IRF8 acts as a
negative regulator
of ICS-containing promoters. This is direct experimental evidence.
supported_by:
- reference_id: PMID:1460054
supporting_text: "The results of transient transfection assays carried out
either in hematopoietic or nonhematopoietic cells suggest that ICSBP acts
as a negative regulatory factor on ICS-containing promoters."
- term:
id: GO:0000122
label: negative regulation of transcription by RNA polymerase II
evidence_type: IDA
original_reference_id: PMID:25122610
review:
summary: >-
IDA annotation from functional characterization of human IRF8 K108E mutation
showing
loss of transcriptional activity.
action: ACCEPT
reason: >-
The study characterized IRF8 function by showing that the K108E mutation causes
loss of transcriptional activity, demonstrating that wild-type IRF8 has transcriptional
regulatory function.
supported_by:
- reference_id: PMID:25122610
supporting_text: "Biochemical characterization of the IRF8(K108E) mutant
in vitro shows that loss of the positively charged side chain at K108
causes loss of nuclear localization and loss of transcriptional activity"
- term:
id: GO:0005634
label: nucleus
evidence_type: IDA
original_reference_id: PMID:25122610
review:
summary: >-
IDA annotation for nuclear localization from the K108E mutation study showing
IRF8
requires nuclear localization for function.
action: ACCEPT
reason: >-
Direct experimental evidence for nuclear localization and its importance for
function.
The K108E mutation causes loss of nuclear localization.
supported_by:
- reference_id: PMID:25122610
supporting_text: "loss of the positively charged side chain at K108 causes
loss of nuclear localization and loss of transcriptional activity"
- term:
id: GO:0005737
label: cytoplasm
evidence_type: IDA
original_reference_id: PMID:25122610
review:
summary: >-
IDA annotation for cytoplasmic localization in resting cells before IFN-gamma
stimulation.
action: ACCEPT
reason: >-
IRF8 is found in the cytoplasm in resting cells. The K108E mutation affects
nuclear
translocation, indicating normal IRF8 shuttles between cytoplasm and nucleus.
supported_by:
- reference_id: PMID:25122610
supporting_text: Functional characterization of the human dendritic
cell immunodeficiency associated with the IRF8(K108E) mutation.
- term:
id: GO:0045944
label: positive regulation of transcription by RNA polymerase II
evidence_type: IDA
original_reference_id: PMID:25122610
review:
summary: >-
IDA annotation for transcriptional activation function, demonstrated by loss
of
transcriptional activity in K108E mutant.
action: ACCEPT
reason: >-
The K108E mutation study showed loss of transcriptional activity, demonstrating
that
wild-type IRF8 can activate transcription.
supported_by:
- reference_id: PMID:25122610
supporting_text: "loss of the positively charged side chain at K108 causes
loss of nuclear localization and loss of transcriptional activity"
- term:
id: GO:0071346
label: cellular response to type II interferon
evidence_type: IDA
original_reference_id: PMID:25122610
review:
summary: >-
IDA annotation for IFN-gamma response, showing IRF8 is involved in interferon-regulated
transcription.
action: ACCEPT
reason: >-
The study shows IRF8 regulates IRF8-bound and IRF8-regulated transcriptional
targets
that are depleted in the patient, demonstrating its role in interferon responses.
supported_by:
- reference_id: PMID:25122610
supporting_text: "depletion of IRF8-bound and IRF8-regulated transcriptional
targets"
- term:
id: GO:0000978
label: RNA polymerase II cis-regulatory region sequence-specific DNA
binding
evidence_type: IDA
original_reference_id: PMID:1460054
review:
summary: >-
IDA annotation for sequence-specific DNA binding to the interferon consensus
sequence (ICS).
action: ACCEPT
reason: >-
The original cloning paper demonstrated that ICSBP binds to ICS elements and
that truncation
of the N-terminus eliminates DNA binding.
supported_by:
- reference_id: PMID:1460054
supporting_text: "Truncated ICSBP lacking the first 33 amino-terminal amino
acids fails to bind to the ICS"
- term:
id: GO:0001227
label: DNA-binding transcription repressor activity, RNA polymerase
II-specific
evidence_type: IDA
original_reference_id: PMID:1460054
review:
summary: >-
IDA annotation for transcriptional repressor activity based on the original
cloning paper.
action: ACCEPT
reason: >-
The original paper established ICSBP/IRF8 as a transcriptional repressor of
ICS-containing
promoters. This molecular function is well-documented.
supported_by:
- reference_id: PMID:1460054
supporting_text: "ICSBP acts as a negative regulatory factor on ICS-containing
promoters"
- term:
id: GO:0005829
label: cytosol
evidence_type: TAS
original_reference_id: Reactome:R-HSA-1015702
review:
summary: >-
TAS annotation from Reactome pathway for expression of IFN-induced genes.
IRF8 is present
in cytosol in unstimulated cells.
action: ACCEPT
reason: >-
Consistent with IDA annotation showing cytoplasmic localization in resting
cells. Cytosol
is a subcompartment of cytoplasm.
- term:
id: GO:0005829
label: cytosol
evidence_type: TAS
original_reference_id: Reactome:R-HSA-1031716
review:
summary: >-
TAS annotation from Reactome pathway for expression of IFNG-stimulated genes.
action: ACCEPT
reason: >-
Duplicate of above annotation from different Reactome pathway. Cytosolic localization
is consistent with other evidence.
- term:
id: GO:0000122
label: negative regulation of transcription by RNA polymerase II
evidence_type: TAS
original_reference_id: PMID:1460054
review:
summary: >-
TAS annotation for transcriptional repression, citing the original ICSBP cloning
paper.
action: ACCEPT
reason: >-
This is a duplicate of the IDA annotation to the same term from the same reference.
The original paper established IRF8 as a transcriptional repressor.
supported_by:
- reference_id: PMID:1460054
supporting_text: Human interferon consensus sequence binding protein
is a negative regulator of enhancer elements common to
interferon-inducible genes.
- term:
id: GO:0000981
label: DNA-binding transcription factor activity, RNA polymerase
II-specific
evidence_type: TAS
original_reference_id: PMID:1460054
review:
summary: >-
TAS annotation for transcription factor activity from the original cloning
paper.
action: ACCEPT
reason: >-
This duplicates IBA and ISA annotations. The original paper established IRF8
as a
DNA-binding transcription factor.
supported_by:
- reference_id: PMID:1460054
supporting_text: Human interferon consensus sequence binding protein
is a negative regulator of enhancer elements common to
interferon-inducible genes.
- term:
id: GO:0006955
label: immune response
evidence_type: TAS
original_reference_id: PMID:8861914
review:
summary: >-
TAS annotation for immune response based on the mouse knockout study showing
immunodeficiency.
action: ACCEPT
reason: >-
The mouse knockout study demonstrated IRF8's essential role in immune function,
including
virus susceptibility and impaired IFN-gamma production.
supported_by:
- reference_id: PMID:8861914
supporting_text: "enhanced susceptibility to virus infections associated
with impaired production of IFN(gamma)"
references:
- id: GO_REF:0000002
title: Gene Ontology annotation through association of InterPro records with
GO terms
findings: []
- id: GO_REF:0000024
title: Manual transfer of experimentally-verified manual GO annotation data
to orthologs by curator judgment of sequence similarity
findings: []
- id: GO_REF:0000033
title: Annotation inferences using phylogenetic trees
findings: []
- id: GO_REF:0000043
title: Gene Ontology annotation based on UniProtKB/Swiss-Prot keyword
mapping
findings: []
- id: GO_REF:0000044
title: Gene Ontology annotation based on UniProtKB/Swiss-Prot Subcellular
Location vocabulary mapping, accompanied by conservative changes to GO
terms applied by UniProt
findings: []
- id: GO_REF:0000052
title: Gene Ontology annotation based on curation of immunofluorescence data
findings: []
- id: GO_REF:0000107
title: Automatic transfer of experimentally verified manual GO annotation
data to orthologs using Ensembl Compara
findings: []
- id: GO_REF:0000113
title: Gene Ontology annotation of human sequence-specific DNA binding
transcription factors (DbTFs) based on the TFClass database
findings: []
- id: GO_REF:0000117
title: Electronic Gene Ontology annotations created by ARBA machine learning
models
findings: []
- id: GO_REF:0000120
title: Combined Automated Annotation using Multiple IEA Methods
findings: []
- id: PMID:1460054
title: Human interferon consensus sequence binding protein is a negative
regulator of enhancer elements common to interferon-inducible genes.
findings:
- statement: IRF8/ICSBP binds to the interferon consensus sequence (ICS)
- statement: Acts as a transcriptional repressor of ICS-containing
promoters
- statement: DNA binding requires the N-terminal domain
- statement: Expressed in hematopoietic cells
- statement: IFN treatment alleviates repression
- id: PMID:21903422
title: Mapping a dynamic innate immunity protein interaction network
regulating type I interferon production.
findings:
- statement: High-throughput interactome mapping study (HI5)
- statement: IRF8 was one of many proteins analyzed
- statement: Study focused on innate immunity network
- id: PMID:25122610
title: Functional characterization of the human dendritic cell
immunodeficiency associated with the IRF8(K108E) mutation.
findings:
- statement: K108E mutation causes loss of nuclear localization
- statement: K108E mutation causes loss of transcriptional activity
- statement: IRF8 localizes to cytoplasm in resting cells
- statement: IRF8 translocates to nucleus upon IFN-gamma stimulation
- statement: K108E causes increased ubiquitination and proteasomal
degradation
- statement: Loss of both activator and repressor functions in mutant
- id: PMID:28473536
title: Impact of cytosine methylation on DNA binding specificities of human
transcription factors.
findings:
- statement: Systematic SELEX study of 542 human TFs
- statement: Determined DNA binding specificities
- statement: IRF8 included in the analysis
- id: PMID:32814053
title: Interactome Mapping Provides a Network of Neurodegenerative Disease
Proteins and Uncovers Widespread Protein Aggregation in Affected Brains.
findings:
- statement: High-throughput interactome study focused on
neurodegeneration
- statement: IRF8 was one of many proteins in the network
- statement: Not specifically relevant to IRF8 core function
- id: PMID:33951726
title: Constrained chromatin accessibility in PU.1-mutated
agammaglobulinemia patients.
findings:
- statement: IRF8 interacts with PU.1/SPI1
- statement: PU.1 and IRF8 cooperate in chromatin accessibility
- statement: Important for B cell development
- id: PMID:8861914
title: Immunodeficiency and chronic myelogenous leukemia-like syndrome in
mice with a targeted mutation of the ICSBP gene.
findings:
- statement: IRF8/ICSBP knockout mice have immunodeficiency
- statement: Enhanced susceptibility to viral infections
- statement: Impaired IFN-gamma production
- statement: Deregulated hematopoiesis with CML-like syndrome
- id: Reactome:R-HSA-1015702
title: Expression of IFN-induced genes
findings: []
- id: Reactome:R-HSA-1031716
title: Expression of IFNG-stimulated genes
findings: []
- id: file:human/IRF8/IRF8-deep-research-falcon.md
title: Deep research report on IRF8
findings: []
core_functions:
- molecular_function:
id: GO:0000981
label: DNA-binding transcription factor activity, RNA polymerase
II-specific
description: >-
IRF8 is a sequence-specific DNA-binding transcription factor that binds ISRE,
EICE, and AICE
regulatory elements to control gene expression.
- molecular_function:
id: GO:0001227
label: DNA-binding transcription repressor activity, RNA polymerase
II-specific
description: >-
IRF8 acts as a transcriptional repressor of interferon-inducible genes, maintaining
submaximal
activity that can be relieved by interferon treatment.
directly_involved_in:
- id: GO:0097028
label: dendritic cell differentiation
- molecular_function:
id: GO:0000981
label: DNA-binding transcription factor activity, RNA polymerase
II-specific
description: >-
IRF8 is essential for the development of conventional DC1 (cDC1) and plasmacytoid
DC (pDC)
populations. Human and mouse deficiency causes absence of these cell types.
directly_involved_in:
- id: GO:0002273
label: plasmacytoid dendritic cell differentiation
- molecular_function:
id: GO:0000981
label: DNA-binding transcription factor activity, RNA polymerase
II-specific
description: >-
IRF8 is required for pDC development, the major producers of type I interferons.
directly_involved_in:
- id: GO:0032479
label: regulation of type I interferon production
- molecular_function:
id: GO:0000981
label: DNA-binding transcription factor activity, RNA polymerase
II-specific
description: >-
IRF8 mediates cellular responses to IFN-gamma by translocating to the nucleus
and
regulating target gene expression.
directly_involved_in:
- id: GO:0071346
label: cellular response to type II interferon
proposed_new_terms: []
suggested_questions:
- question: What are the specific enhancer elements and chromatin
accessibility changes controlled by IRF8 in human DC progenitors?
- question: How do IRF8 interactions with different partners (PU.1 vs BATF)
determine activator vs repressor function?
- question: What is the relationship between IRF8 and MHC class II antigen
processing gene regulation in human DCs?
suggested_experiments:
- description: ChIP-seq analysis of IRF8 binding sites in human
monocyte-derived DCs with and without IFN-gamma stimulation
- description: CRISPR screens in human hematopoietic progenitors to identify
IRF8-dependent genes for DC differentiation
- description: Structural studies of IRF8-DNA-partner complexes to understand
composite element recognition